Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTXNASDAQ:ATHXNASDAQ:ENVBNYSE:OGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$1.38-4.8%$1.99$1.34▼$27,200.00$2.93M1.49799,974 shs79,514 shsATHXAthersys$0.00$0.01▼$1.99$833K-0.91.77 million shs1 shsENVBEnveric Biosciences$1.21-2.4%$1.26$1.01▼$11.55$2.99M0.53773,056 shs100,804 shsOGENOragenics$4.36-5.8%$5.27$3.12▼$75.60$3.12M0.94105,666 shs80,798 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-4.83%-10.39%-16.87%+6,765.67%-99.99%ATHXAthersys0.00%0.00%0.00%0.00%-75.00%ENVBEnveric Biosciences-2.42%-6.92%-7.63%-30.06%-89.40%OGENOragenics-5.83%+1.87%-25.77%-48.10%-91.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADTXAditxt0.9973 of 5 stars0.05.00.00.02.50.00.6ATHXAthersysN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences2.0396 of 5 stars3.52.00.00.01.80.01.3OGENOragenics0.4309 of 5 stars0.04.00.00.02.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 0.00N/AN/AN/AATHXAthersys 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00726.45% UpsideOGENOragenics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxt$55.32K52.88N/AN/A$2,687.49 per share0.00ATHXAthersys$146K0.00N/AN/A($1.33) per share0.00ENVBEnveric BiosciencesN/AN/AN/AN/A$10.71 per shareN/AOGENOragenics$40K77.94N/AN/A$0.61 per share7.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$32.38MN/A0.00∞N/AN/A-439.07%-122.96%8/18/2025 (Estimated)ATHXAthersys-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/AENVBEnveric Biosciences-$17.29M-$38.38N/AN/AN/AN/A-221.54%-164.32%8/11/2025 (Estimated)OGENOragenics-$20.66M-$33.63N/A∞N/AN/A-2,087.95%-486.56%N/ALatest ATHX, ENVB, ADTX, and OGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ADTXAditxt-$26,400.00-$8.12+$26,391.88-$8.12$0.43 million$0.00 million5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/AATHXAthersysN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.090.08ATHXAthersysN/A0.060.06ENVBEnveric BiosciencesN/A5.175.17OGENOragenicsN/A1.931.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%ATHXAthersys19.35%ENVBEnveric Biosciences13.82%OGENOragenics18.71%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%ATHXAthersys0.03%ENVBEnveric Biosciences1.10%OGENOragenics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt602.12 million14.23 millionNo DataATHXAthersys2461.72 million61.70 millionNo DataENVBEnveric Biosciences202.47 million656,000Not OptionableOGENOragenics5715,00010.98 millionN/AATHX, ENVB, ADTX, and OGEN HeadlinesRecent News About These CompaniesOragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 12 at 12:21 AM | nasdaq.comOragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 10, 2025 | finance.yahoo.comOragenics (NYSE:OGEN) Shares Down 4.6% - What's Next?June 6, 2025 | americanbankingnews.comOragenics (NYSE:OGEN) Trading Down 4.6% - Time to Sell?June 6, 2025 | marketbeat.comOragenics Inc.June 4, 2025 | wsj.comOragenics, Inc. Announces One-for-Thirty Reverse Stock SplitMay 29, 2025 | finance.yahoo.comOragenics Hosts Neurotrauma Medicine Webinar PresentationMay 20, 2025 | tipranks.comOragenics gains Australia’s nod for concussion therapy trialMay 15, 2025 | uk.investing.comOragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion TreatmentMay 14, 2025 | nasdaq.comOragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in AustraliaMay 13, 2025 | globenewswire.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion ...May 12, 2025 | gurufocus.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic VisionMay 12, 2025 | globenewswire.comOragenics Appoints Janet Huffman as CEO and CFOMay 2, 2025 | tipranks.comOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury ConferenceApril 23, 2025 | manilatimes.netOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN ...April 23, 2025 | gurufocus.comOragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion TrialApril 9, 2025 | finance.yahoo.comOragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery SummitApril 7, 2025 | globenewswire.comOragenics provides Q1 shareholder update on strategic financial progressMarch 28, 2025 | markets.businessinsider.comOragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial ProgressMarch 27, 2025 | globenewswire.comOragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-KMarch 18, 2025 | globenewswire.comOragenics submits IB for Phase II clinical trial of ONP-002 in mTBIMarch 6, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATHX, ENVB, ADTX, and OGEN Company DescriptionsAditxt NASDAQ:ADTX$1.38 -0.07 (-4.83%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.42 +0.04 (+2.61%) As of 06/13/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Athersys NASDAQ:ATHXAthersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.Enveric Biosciences NASDAQ:ENVB$1.21 -0.03 (-2.42%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.23 +0.02 (+1.65%) As of 06/13/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Oragenics NYSE:OGEN$4.36 -0.27 (-5.83%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.32 -0.04 (-1.03%) As of 06/13/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
